Enovis (NYSE:ENOV) Issues FY24 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY24 earnings guidance on Thursday morning. The company provided EPS guidance of $2.52-$2.67 for the period, compared to the consensus EPS estimate of $2.60. The company issued revenue guidance of $2.06-$2.16 billion, compared to the consensus revenue estimate of $2.12 billion.

Analyst Ratings Changes

A number of equities analysts have weighed in on ENOV shares. Needham & Company LLC restated a buy rating and issued a $82.00 price target on shares of Enovis in a report on Friday. Stephens began coverage on shares of Enovis in a research note on Tuesday, February 13th. They issued an overweight rating and a $72.00 target price for the company. UBS Group assumed coverage on shares of Enovis in a report on Monday, January 22nd. They set a buy rating and a $75.00 price target for the company. Wells Fargo & Company boosted their price objective on shares of Enovis from $73.00 to $79.00 and gave the stock an overweight rating in a report on Friday, February 23rd. Finally, Canaccord Genuity Group raised their target price on Enovis from $73.00 to $75.00 and gave the company a buy rating in a research note on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of Buy and a consensus price target of $75.43.

Enovis Stock Down 1.6 %

ENOV stock traded down $0.86 during mid-day trading on Friday, hitting $51.27. 1,147,518 shares of the company were exchanged, compared to its average volume of 520,993. The firm has a fifty day simple moving average of $59.15 and a 200 day simple moving average of $55.74. Enovis has a twelve month low of $43.04 and a twelve month high of $66.14. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.10 and a quick ratio of 1.16.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, hitting the consensus estimate of $0.50. The business had revenue of $516.00 million for the quarter, compared to analysts’ expectations of $505.62 million. Enovis had a negative net margin of 4.51% and a positive return on equity of 3.98%. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.44 earnings per share. Equities research analysts expect that Enovis will post 2.6 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.